Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 625 to 631 of 631 entries
Sorted by: Best Match Show Resources per page
Urological Melanoma: A Comprehensive Review of a Rare Subclass of Mucosal Melanoma with Emphasis on Differential Diagnosis and Therapeutic Approaches.

Cancers

Cazzato G, Colagrande A, Cimmino A, Caporusso C, Candance PMV, Trabucco SMR, Zingarelli M, Lorusso A, Marrone M, Stellacci A, Arezzo F, Marzullo A, Serio G, Filoni A, Bonamonte D, Romita P, Foti C, Lettini T, Loizzi V, Cormio G, Resta L, Rossi R, Ingravallo G.
PMID: 34503234
Cancers (Basel). 2021 Sep 02;13(17). doi: 10.3390/cancers13174424.

Melanoma is reported as the 19th most common cancer worldwide, with estimated age-standardized incidence rates of 2.8-3.1 per 100,000. Although the origin is most frequently cutaneous, mucosal melanoma has been described several times in literature, and despite its rarity...

Cite
Cazzato G, Colagrande A, Cimmino A, et al. Urological Melanoma: A Comprehensive Review of a Rare Subclass of Mucosal Melanoma with Emphasis on Differential Diagnosis and Therapeutic Approaches. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174424.
Cazzato, G., Colagrande, A., Cimmino, A., Caporusso, C., Candance, P. M. V., Trabucco, S. M. R., Zingarelli, M., Lorusso, A., Marrone, M., Stellacci, A., Arezzo, F., Marzullo, A., Serio, G., Filoni, A., Bonamonte, D., Romita, P., Foti, C., Lettini, T., Loizzi, V., Cormio, G., Resta, L., Rossi, R., & Ingravallo, G. (2021). Urological Melanoma: A Comprehensive Review of a Rare Subclass of Mucosal Melanoma with Emphasis on Differential Diagnosis and Therapeutic Approaches. Cancers, 13(17), . https://doi.org/10.3390/cancers13174424
Cazzato, Gerardo, et al. "Urological Melanoma: A Comprehensive Review of a Rare Subclass of Mucosal Melanoma with Emphasis on Differential Diagnosis and Therapeutic Approaches." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174424
Cazzato G, Colagrande A, Cimmino A, Caporusso C, Candance PMV, Trabucco SMR, Zingarelli M, Lorusso A, Marrone M, Stellacci A, Arezzo F, Marzullo A, Serio G, Filoni A, Bonamonte D, Romita P, Foti C, Lettini T, Loizzi V, Cormio G, Resta L, Rossi R, Ingravallo G. Urological Melanoma: A Comprehensive Review of a Rare Subclass of Mucosal Melanoma with Emphasis on Differential Diagnosis and Therapeutic Approaches. Cancers (Basel). 2021 Sep 02;13(17). doi: 10.3390/cancers13174424. PMID: 34503234; PMCID: PMC8431506.
Copy Download .nbib Format: NLM
Human factors in ECLS - A keystone for safety and quality - A narrative review for ECLS providers.

Artificial organs

Swol J, Brodie D, Willers A, Zakhary B, Belezzo J, Shinar Z, Weingart SD, Haft JW, Lorusso R, Peek GJ.
PMID: 34738639
Artif Organs. 2022 Jan;46(1):40-49. doi: 10.1111/aor.14095. Epub 2021 Nov 05.

INTRODUCTION: Although the technology used for extracorporeal life support (ECLS) has improved greatly in recent years, the application of these devices to the patient is quite complex and requires extensive training of team members both individually and together. Human...

Cite
Swol J, Brodie D, Willers A, et al. Human factors in ECLS - A keystone for safety and quality - A narrative review for ECLS providers. Artif Organs. 2021;46(1):40-49doi: 10.1111/aor.14095.
Swol, J., Brodie, D., Willers, A., Zakhary, B., Belezzo, J., Shinar, Z., Weingart, S. D., Haft, J. W., Lorusso, R., & Peek, G. J. (2022). Human factors in ECLS - A keystone for safety and quality - A narrative review for ECLS providers. Artificial organs, 46(1), 40-49. https://doi.org/10.1111/aor.14095
Swol, Justyna, et al. "Human factors in ECLS - A keystone for safety and quality - A narrative review for ECLS providers." Artificial organs vol. 46,1 (2022): 40-49. doi: https://doi.org/10.1111/aor.14095
Swol J, Brodie D, Willers A, Zakhary B, Belezzo J, Shinar Z, Weingart SD, Haft JW, Lorusso R, Peek GJ. Human factors in ECLS - A keystone for safety and quality - A narrative review for ECLS providers. Artif Organs. 2022 Jan;46(1):40-49. doi: 10.1111/aor.14095. Epub 2021 Nov 05. PMID: 34738639.
Copy Download .nbib Format: NLM
Sars-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte-Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and Thrombophilia.

Microorganisms

Balzanelli MG, Distratis P, Dipalma G, Vimercati L, Inchingolo AD, Lazzaro R, Aityan SK, Maggiore ME, Mancini A, Laforgia R, Pezzolla A, Tomassone D, Pham VH, Iacobone D, Castrignano A, Scarano A, Lorusso F, Tafuri S, Migliore G, Inchingolo AM, Nguyen KCD, Toai TC, Inchingolo F, Isacco CG.
PMID: 34442710
Microorganisms. 2021 Jul 30;9(8). doi: 10.3390/microorganisms9081632.

To date, several cases of thrombosis have been confirmed to be related to Sars-CoV-2 infection. Multiple attempts detected the prolonged occurrence of Sars-CoV-2 viral RNA (long COVID) in whole blood suggesting that virus byproducts may remain within cells and...

Cite
Balzanelli MG, Distratis P, Dipalma G, et al. Sars-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte-Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and Thrombophilia. Microorganisms. 2021;9(8)doi: 10.3390/microorganisms9081632.
Balzanelli, M. G., Distratis, P., Dipalma, G., Vimercati, L., Inchingolo, A. D., Lazzaro, R., Aityan, S. K., Maggiore, M. E., Mancini, A., Laforgia, R., Pezzolla, A., Tomassone, D., Pham, V. H., Iacobone, D., Castrignano, A., Scarano, A., Lorusso, F., Tafuri, S., Migliore, G., Inchingolo, A. M., Nguyen, K. C. D., Toai, T. C., Inchingolo, F., & Isacco, C. G. (2021). Sars-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte-Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and Thrombophilia. Microorganisms, 9(8), . https://doi.org/10.3390/microorganisms9081632
Balzanelli, Mario Giosuè, et al. "Sars-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte-Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and Thrombophilia." Microorganisms vol. 9,8 (2021). doi: https://doi.org/10.3390/microorganisms9081632
Balzanelli MG, Distratis P, Dipalma G, Vimercati L, Inchingolo AD, Lazzaro R, Aityan SK, Maggiore ME, Mancini A, Laforgia R, Pezzolla A, Tomassone D, Pham VH, Iacobone D, Castrignano A, Scarano A, Lorusso F, Tafuri S, Migliore G, Inchingolo AM, Nguyen KCD, Toai TC, Inchingolo F, Isacco CG. Sars-CoV-2 Virus Infection May Interfere CD34+ Hematopoietic Stem Cells and Megakaryocyte-Erythroid Progenitors Differentiation Contributing to Platelet Defection towards Insurgence of Thrombocytopenia and Thrombophilia. Microorganisms. 2021 Jul 30;9(8). doi: 10.3390/microorganisms9081632. PMID: 34442710; PMCID: PMC8400074.
Copy Download .nbib Format: NLM
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.

JAMA oncology

Falandry C, Rousseau F, Mouret-Reynier MA, Tinquaut F, Lorusso D, Herrstedt J, Savoye AM, Stefani L, Bourbouloux E, Sverdlin R, D'Hondt V, Lortholary A, Brachet PE, Zannetti A, Malaurie E, Venat-Bouvet L, Trédan O, Mourey L, Pujade-Lauraine E, Freyer G.
PMID: 33885718
JAMA Oncol. 2021 Jun 01;7(6):853-861. doi: 10.1001/jamaoncol.2021.0696.

IMPORTANCE: Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an approach could have a detrimental effect on outcomes for these patients.OBJECTIVE: To compare the feasibility, efficacy, and safety...

Cite
Falandry C, Rousseau F, Mouret-Reynier MA, et al. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial. JAMA Oncol. 2021;7(6):853-861doi: 10.1001/jamaoncol.2021.0696.
Falandry, C., Rousseau, F., Mouret-Reynier, M. A., Tinquaut, F., Lorusso, D., Herrstedt, J., Savoye, A. M., Stefani, L., Bourbouloux, E., Sverdlin, R., D'Hondt, V., Lortholary, A., Brachet, P. E., Zannetti, A., Malaurie, E., Venat-Bouvet, L., Trédan, O., Mourey, L., Pujade-Lauraine, E., Freyer, G. (2021). Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial. JAMA oncology, 7(6), 853-861. https://doi.org/10.1001/jamaoncol.2021.0696
Falandry, Claire, et al. "Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial." JAMA oncology vol. 7,6 (2021): 853-861. doi: https://doi.org/10.1001/jamaoncol.2021.0696
Falandry C, Rousseau F, Mouret-Reynier MA, Tinquaut F, Lorusso D, Herrstedt J, Savoye AM, Stefani L, Bourbouloux E, Sverdlin R, D'Hondt V, Lortholary A, Brachet PE, Zannetti A, Malaurie E, Venat-Bouvet L, Trédan O, Mourey L, Pujade-Lauraine E, Freyer G. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial. JAMA Oncol. 2021 Jun 01;7(6):853-861. doi: 10.1001/jamaoncol.2021.0696. PMID: 33885718; PMCID: PMC8063137.
Copy Download .nbib Format: NLM
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.

Clinical cancer research : an official journal of the American Association for Cancer Research

Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP.
PMID: 34518310
Clin Cancer Res. 2021 Dec 01;27(23):6366-6375. doi: 10.1158/1078-0432.CCR-20-4185. Epub 2021 Sep 13.

PURPOSE: Monopolar spindle 1 (MPS1) kinase inhibitor, BAY 1217389 (BAY) synergizes with paclitaxel. This phase I study assessed the combination of BAY with paclitaxel using a novel randomized continuous reassessment method (rCRM) to improve dose determination.PATIENTS AND METHODS: Patients...

Cite
Atrafi F, Boix O, Subbiah V, et al. A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clin Cancer Res. 2021;27(23):6366-6375doi: 10.1158/1078-0432.CCR-20-4185.
Atrafi, F., Boix, O., Subbiah, V., Diamond, J. R., Chawla, S. P., Tolcher, A. W., LoRusso, P. M., Eder, J. P., Gutierrez, M., Sankhala, K., Rajagopalan, P., Genvresse, I., Langer, S., Mathijssen, R. H. J., Verweij, J., Bruns, I., & Lolkema, M. P. (2021). A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(23), 6366-6375. https://doi.org/10.1158/1078-0432.CCR-20-4185
Atrafi, Florence, et al. "A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,23 (2021): 6366-6375. doi: https://doi.org/10.1158/1078-0432.CCR-20-4185
Atrafi F, Boix O, Subbiah V, Diamond JR, Chawla SP, Tolcher AW, LoRusso PM, Eder JP, Gutierrez M, Sankhala K, Rajagopalan P, Genvresse I, Langer S, Mathijssen RHJ, Verweij J, Bruns I, Lolkema MP. A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. Clin Cancer Res. 2021 Dec 01;27(23):6366-6375. doi: 10.1158/1078-0432.CCR-20-4185. Epub 2021 Sep 13. PMID: 34518310.
Copy Download .nbib Format: NLM
CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?.

La Radiologia medica

Mirabile A, Lucarelli NM, Sollazzo EP, Stabile Ianora AA, Sardaro A, Mirabile G, Lorusso F, Racanelli V, Maggialetti N, Scardapane A.
PMID: 34518985
Radiol Med. 2021 Sep 13; doi: 10.1007/s11547-021-01416-x. Epub 2021 Sep 13.

PURPOSE: To assess the percentage of computed tomography pulmonary angiography (CTPA) procedures that could have been avoided by methodical application of the Revised Geneva Score (RGS) coupled with age-adjusted D-dimer cut-offs rather than only clinical judgment in Emergency Department...

Cite
Mirabile A, Lucarelli NM, Sollazzo EP, et al. CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?. Radiol Med. 2021;doi: 10.1007/s11547-021-01416-x.
Mirabile, A., Lucarelli, N. M., Sollazzo, E. P., Stabile Ianora, A. A., Sardaro, A., Mirabile, G., Lorusso, F., Racanelli, V., Maggialetti, N., & Scardapane, A. (2021). CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?. La Radiologia medica, . https://doi.org/10.1007/s11547-021-01416-x
Mirabile, Alessandra, et al. "CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?." La Radiologia medica vol. (2021). doi: https://doi.org/10.1007/s11547-021-01416-x
Mirabile A, Lucarelli NM, Sollazzo EP, Stabile Ianora AA, Sardaro A, Mirabile G, Lorusso F, Racanelli V, Maggialetti N, Scardapane A. CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?. Radiol Med. 2021 Sep 13; doi: 10.1007/s11547-021-01416-x. Epub 2021 Sep 13. PMID: 34518985.
Copy Download .nbib Format: NLM
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.

Cancer medicine

Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL.
PMID: 34549539
Cancer Med. 2021 Oct;10(20):7162-7173. doi: 10.1002/cam4.4260. Epub 2021 Sep 21.

BACKGROUND: The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum-based chemotherapy and baseline disease.METHODS: Patients were randomized 2:1 to receive either oral rucaparib at a dosage...

Cite
Oaknin A, Oza AM, Lorusso D, et al. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Med. 2021;10(20):7162-7173doi: 10.1002/cam4.4260.
Oaknin, A., Oza, A. M., Lorusso, D., Aghajanian, C., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., Leary, A., Holloway, R. W., Amenedo Gancedo, M., Fong, P. C., Goh, J. C., O'Malley, D. M., Armstrong, D. K., Banerjee, S., García-Donas, J., Swisher, E. M., Cameron, T., Maloney, L., Goble, S., Ledermann, J. A., & Coleman, R. L. (2021). Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer medicine, 10(20), 7162-7173. https://doi.org/10.1002/cam4.4260
Oaknin, Ana, et al. "Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety." Cancer medicine vol. 10,20 (2021): 7162-7173. doi: https://doi.org/10.1002/cam4.4260
Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Med. 2021 Oct;10(20):7162-7173. doi: 10.1002/cam4.4260. Epub 2021 Sep 21. PMID: 34549539; PMCID: PMC8525125.
Copy Download .nbib Format: NLM
Showing 625 to 631 of 631 entries